PRAETEGO, INC.
DURHAM, NC · Founded 2017 · CIK 0001736121 · Biotech · Private
PTG-630, an oral small molecule AGE inhibitor and antioxidant therapeutic for diabetic retinopathy
- Grants
- $5.8M
- 9 awards
- Sector median: 1
- Raised
- $783K
- 4 Form D · Jan 2021
- 68 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 6
- 1 granted · 5 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $20,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of novel Amadorins for Diabetic Peripheral Neuropathy | $299,825 | |
| Private capital raised | Form D · SEC | $250,000 | |
| Private capital raised | Form D · SEC | $100,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of novel Amadorins for Diabetic Peripheral Neuropathy | $874,423 | |
| Private capital raised | Form D · SEC | $412,703 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of novel Amadorins for Diabetic Peripheral Neuropathy | $458,155 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of novel Amadorins for Diabetic Peripheral Neuropathy | $895,610 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of novel Amadorins for Diabetic Peripheral Neuropathy | $369,966 | |
| Federal grant | Department of Health and Human Services · Phase II · Amadorins for Ameliorating Alzheimer's Disease and Related Dementias (ADRD) | $1,259,042 | |
| Federal grant | Department of Health and Human Services · Phase I · Amadorins as a Novel Oral Therapeutic for Diabetic Retinopathy | $298,940 | |
| Federal grant | Department of Health and Human Services · Phase II · Amadorins for Ameliorating Alzheimer's Disease and Related Dementias (ADRD) | $50,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Amadorins for Ameliorating Alzheimer's Disease and Related Dementias (ADRD) | $1,246,076 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2581 | RAPHAEL PHARMACEUTICALS LLC | — | — |
| 2582 | KaloCyte Inc | — | $800K |
| 2583 | Metagenomi | — | — |
| 2584 | PRAETEGO, INC. | — | $783K |
| 2585 | Indigo Biosciences Inc. | — | $782K |
| 2586 | Bit Discovery, Inc. | — | $760K |
| 2587 | AAKHA BIOLOGICS INC. | — | $750K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- JOHN GRIFFINExecutive Officer
- Raja KhalifahDirector · Executive Officer
- RAJA KHALIFAHExecutive Officer
- Pepper LandsonDirector · Executive Officer
- PEPPER LANDSONDirector · Executive Officer
- JOHN MAZURDirector
- JOHN MAZUR, MDDirector
Patents
- Inhibitors Of Advanced Glycation End Productsapplication
- Inhibitors Of Advanced Glycation End Productsapplication
- Methods for Treating Neurodegenerative Disordersapplication
- Inhibitors of Advanced Glycation End Productsgranted
- Methods For Treating Neurodegenerative Disordersapplication
- Inhibitors Of Advanced Glycation End Productsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.